Estevan Kiernan | Associate Director, Emerging Clinical Applications-Oncology

Estevan Kiernan, Associate Director, Emerging Clinical Applications-Oncology, Illumina

Estevan Kiernan has worked in infectious disease, genetic disease and oncology molecular diagnostics 15+ years at leading biotech companies including Thermo Fisher/Life Technologies and Abbott. For the Last 7 years he has worked at Illumina to identify future clinical applications and work globally with medical societies and private/public partnerships to lower the barriers for identified applications (ex MRD, Screening, CGP, TMB, HRD harmonization, WGS in Heme). He is currently the chair of multiple working groups within BloodPAC and GUIDE.MRD consortium on implementation, market access and patient accessibility on ctDNA initiatives as well as managing ongoing relationships/projects with multiple medical societies including AMP,FOCR,NCCN, AACR and CAP.  


Day 2 - November 29 @ 09:15

Keynote Panel: Moving to the left: The maturing applications of ct & cf DNA in oncology

  • What progress has been made? Recent approvals.
  • As yet untapped potential uses of ctDNA in oncology
  • Success in prediction but difficulty of use in later stage development
  • Do certain phenotypes amongst circulating immune cells dictate responsiveness to certain IO drugs or combinations?

Day 2 - November 29 @ 17:00

Moving From the Lab to the Clinic: Clinical Implementation Challenges of CPG, MRD and Screening

last published: 02/Jan/24 12:15 GMT

back to speakers